Indolyl Hydroxamates for Neurodegenerative Disorder Treatment

The patent applies preliminary action by administering the indolyl hydroxamate compound before significant neuronal loss occurs, aiming to prevent and attenuate neurodegeneration rather than treat advanced stages. The compound is administered at early stages of neurodegenerative disorders to protect neurons from degradation and prevent irreversible damage, thereby resolving the contradiction between current therapeutic insufficiency and neuronal loss.

The patent applies universality by developing an indolyl hydroxamate compound that demonstrates therapeutic potential across multiple neurodegenerative disorders including Huntington's disease, Alzheimer's disease, and Parkinson's disease. The compound's mechanism of action targets common pathophysiological features such as neuronal degradation and oxidative stress, making it potentially effective for multiple disease types simultaneously, thus resolving the contradiction of lacking therapeutic options.

The patent applies preliminary anti-action by using the indolyl hydroxamate compound to counteract and prevent neuronal degradation before it becomes irreversible. The compound works by protecting neurons from oxidative stress, inflammation, and other degenerative processes, thereby attenuating the progression of neurodegeneration and preserving neuronal function, which resolves the contradiction between functional preservation and disease progression.